DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Completed

Conditions: Type 2 Diabetes Mellitus
Chronic Kidney Disease

Interventions: Drug: Finerenone (Kerendia, BAY948862)

First Posted Date: 2023-01-30

Last Posted Date: 2024-10-18

Lead Sponsor: Bayer

Target Recruit Count: 15948

Registration Number: NCT05703880

Locations: 🇺🇸
Optum electronic health records (EHR) database, Eden Prairie, Minnesota, United States
🇺🇸
OM1 Real-World Data Cloud (RWDC), Boston, Massachusetts, United States

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

Phase 4

Active, not recruiting

Conditions: Type 2 Diabetes Mellitus
Chronic Kidney Disease

Interventions: Drug: Finerenone (Kerendia, BAY94-8862)

First Posted Date: 2023-01-30

Last Posted Date: 2025-05-06

Lead Sponsor: Bayer

Target Recruit Count: 200

Registration Number: NCT05705271

Locations: 🇮🇳
Dr Balabhai Nanavati Hospital, Mumbai, Maharashtra,, Maharashtra, India
🇮🇳
Bhate Hospital, Karnataka, Belagavi, India
🇮🇳
Kempegowda Institute of Medical Sciences Hospital & R C, Bangalore, Karnataka, India

and more 14 locations

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Recruiting

Conditions: Retinopathy of Prematurity
Newborns
Infants

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2023-01-30

Last Posted Date: 2025-05-20

Lead Sponsor: Bayer

Target Recruit Count: 75

Registration Number: NCT05705258

Locations: 🇯🇵
Many locations, Multiple Locations, Japan

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

Phase 3

Active, not recruiting

Conditions: Prevention of Ischemic Stroke
Acute Non-cardioembolic Ischemic Stroke
High-risk Transient Ischemic Attack

Interventions: Drug: Asundexian (BAY2433334)
Drug: Placebo

First Posted Date: 2023-01-17

Last Posted Date: 2025-05-20

Lead Sponsor: Bayer

Target Recruit Count: 12300

Registration Number: NCT05686070

Locations: 🇯🇵
Kohnan Hospital, Sendai, Miyagi, Japan
🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
🇨🇳
Wuxi No.2 People's Hospital, Wuxi, Jiangsu, China

and more 737 locations

A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions

Recruiting

Conditions: Chronic Heart Failure

Interventions: Drug: Standard of care
Drug: Vericiguat (Verquvo, BAY1021189)

First Posted Date: 2022-12-28

Last Posted Date: 2025-04-30

Lead Sponsor: Bayer

Target Recruit Count: 1400

Registration Number: NCT05666518

Locations: 🇯🇵
Japanese registries, Multiple Locations, Many Locations, Japan

A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

Phase 4

Completed

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Worsening Heart Failure

Interventions: Drug: Vericiguat (Verquvo, BAY1021189)

First Posted Date: 2022-12-20

Last Posted Date: 2024-10-08

Lead Sponsor: Bayer

Target Recruit Count: 205

Registration Number: NCT05658458

Locations: 🇮🇳
Max Super Speciality Hospital, Saket, New Delhi, Delhi, India
🇮🇳
Safdarjung Hospital, New Delhi, Delhi, India
🇮🇳
Vijan Cardiac & Critical Care Centre, Nashik, Maharashtra, India

and more 9 locations

A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Zabedosertib (BAY1834845)
Drug: Placebo to zabedosertib (BAY1834845)

First Posted Date: 2022-12-19

Last Posted Date: 2025-02-18

Lead Sponsor: Bayer

Target Recruit Count: 77

Registration Number: NCT05656911

Locations: 🇺🇸
NorthShore University HealthSystem | Skokie Hospital - Dermatology Department, Skokie, Illinois, United States
🇺🇸
Beth Israel Deaconess Medical Center - Dermatology, Boston, Massachusetts, United States
🇺🇸
University of Cincinnati College of Medicine - Dermatology, Cincinnati, Ohio, United States

and more 19 locations

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Phase 3

Terminated

Conditions: Prevention of Stroke or Systemic Embolism
Atrial Fibrillation

Interventions: Drug: Asundexian (BAY2433334)
Drug: Apixaban
Drug: Apixaban matching placebo
Drug: Asundexian matching placebo

First Posted Date: 2022-12-08

Last Posted Date: 2024-12-09

Lead Sponsor: Bayer

Target Recruit Count: 14830

Registration Number: NCT05643573

Locations: 🇨🇳
Hwa Mei Hospital, University of Chinese Academy Sciences, Ningbo, Zhejiang, China
🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
🇨🇳
Beijing Tongren Hospital, Capital Medical University (West), Beijing, China

and more 1066 locations

An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.

Recruiting

Conditions: Hemophilia A
Prophylaxis of Bleeding

Interventions: Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)

First Posted Date: 2022-12-08

Last Posted Date: 2025-05-13

Lead Sponsor: Bayer

Target Recruit Count: 33

Registration Number: NCT05643560

Locations: 🇮🇹
Many Locations, Multiple Locations, Italy

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Completed

Conditions: Type 2 Diabetes
Chronic Kidney Disease

Interventions: Drug: Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Drug: Finerenone (Kerendia, BAY94-8862)

First Posted Date: 2022-12-07

Last Posted Date: 2024-01-08

Lead Sponsor: Bayer

Target Recruit Count: 17847

Registration Number: NCT05640180

Locations: 🇺🇸
Bayer, Whippany, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy